Drug Trial Radar · NCT03603262
Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC
Last checked: Nov 19, 2026Latest source record: Jan 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
85
Planned (sponsor's estimate)
Start
Apr 25, 2018
Primary completion
Dec 2019
Study completion Dec 2019
Sponsor
- Lead sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 27, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label study of SH-1028 with dose escalation and dose expansion cohorts in locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients who have progressed following prior therapy with an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor (TKI) agent.
Conditions
- Non-small Cell Lung Cancer
Interventions
SH-1028Drug
Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (100mg,200mg,300mg,400mg) of SH-1028.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD)Time frame: Within the first 28 days of treatment
- Incidence of Dose Limiting Toxicity (DLT)Time frame: Within the first 28 days of treatment
- Area under the plasma concentration versus time curve (AUC) of SH-1028Time frame: 4 weeks
- Elimination half-life(T1/2) of SH-1028Time frame: 4 weeks
- Maximum (or peak) concentration of SH-1028Time frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.